fexofenadine has been researched along with tacrolimus in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Annaert, P; Bouillon, T; de Loor, H; Kuypers, D; Vanhove, T | 1 |
De, D; Handa, S; Mahajan, R; Ningombam, A; Srivastava, N | 1 |
1 review(s) available for fexofenadine and tacrolimus
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for fexofenadine and tacrolimus
Article | Year |
---|---|
Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Female; Humans; Kidney Transplantation; Liver-Specific Organic Anion Transporter 1; Male; Midazolam; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Polymorphism, Single Nucleotide; Solute Carrier Organic Anion Transporter Family Member 1B3; Tacrolimus; Terfenadine; Young Adult | 2017 |
Addition of oral fexofenadine to topical therapy leads to a significantly greater reduction in the serum interleukin-31 levels in mild to moderate paediatric atopic dermatitis.
Topics: Administration, Topical; Child; Dermatitis, Atopic; Double-Blind Method; Humans; Interleukins; Prospective Studies; Tacrolimus; Terfenadine; Treatment Outcome | 2022 |
1 other study(ies) available for fexofenadine and tacrolimus
Article | Year |
---|---|
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |